The Pinā¢ Platform provides a unique opportunity to conduct both proprietary in-house development programs as well as forming partnerships to exploit the modularity of the concept.
CYTEA BIO has elected to initiate a lead development program using armed human allogeneic natural killer cells with Pinā¢ engineered Ā anti-EGFR antibody Ā for the treatment of glioblastoma multiforme.
GLIOBLASTOMA
New patients diagnosed a year
12-15
Months of median overall survival
Effector cell (target)
Indication
Research
ind-enabling
Clinical
NK (EGFR)
Glioblastoma multiforme
NK (EGFR)
EGFR + solid tumors
TBD
Solid tumors, auto-immune & inflammatory diseases
NK (CD20)
Lymphoma
Challenges and Innovations in Glioblastoma Multiforme Treatment
To improve patient outcomes and extend survival rates, there is a critical need to focus on appropriate therapeutic niches which navigate the intricacies of GBM. CYTEA BIO believes that tumor vulnerability immediately following excision surgery is one such niche where administered cytotoxic therapeutic cells can effect a more complete removal of tumor tissue than surgery alone, particularly in the margins between the tumor and normal brain tissue. Evidence suggests that more complete removal of tumor tissue is strongly correlated with extended survival. However, extending surgery into functional brain tissue is contra-indicated, even for the best surgeons. Developing a cellular therapy that can effectively improve residual tumor removal even in problematic situations is essential for offering renewed hope to patients grappling with the devastating impact of this formidable brain cancer.
Applications & Grades
- development of a new approach for glioblastoma multiforme (GBM) treatment
- PIN platform for GBM treatment
- Expanded clinical opportunities and potential benefits
CYTEA BIO envisions overcoming obstacles in cancer treatment through cellular immunotherapy, leading the development of a novel product based on its Pinā¢ Platform for Glioblastoma Multiforme (GBM). This groundbreaking approach targets residual tumor depletion and is likely to delay recurrence as a second-line treatment post-surgery. Tailoring targeting ligands to tumor characteristics determined by biopsy enhances precision. Success in establishing the Pinā¢ Platform for GBM could pave the way for more effective generations of products, establishing a valuable asset base for CYTEA BIO. Demonstrating safety and efficacy in GBM treatment not only addresses a critical patient need but also presents opportunities for broader clinical applications, benefiting patients across various cancers.
